Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Company Overview - Coherus BioSciences (NASDAQ: CHRS) is focused on immunotherapy and aims to expand the market for their PD-1 antibody while developing novel treatment options for solid tumors [1] Recent Performance - The company has recently experienced a recovery, indicating potential positive momentum in its operations and market position [1]